RecruitingPhase 2NCT06835387
Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors
Studying Rare carcinoma of small intestine
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Tiago Biachi de Castria
- Principal Investigator
- Tiago Biachi de Castria, MD, PhDMoffitt Cancer Center
- Intervention
- Nanoliposomal irinotecan(drug)
- Enrollment
- 36 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2028
Study locations (5)
- Moffitt Cancer Center, Tampa, Florida, United States
- University of Illinois Cancer Center, Chicago, Illinois, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- Atlantic Health System, Morristown, New Jersey, United States
- Virginia Commonwealth University, Richmond, Virginia, United States
Collaborators
Ipsen · H. Lee Moffitt Cancer Center and Research Institute
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06835387 on ClinicalTrials.govOther trials for Rare carcinoma of small intestine
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07347314Enfortumab Vedotin in Patients With Advanced Small Bowel Adenocarcinoma Refractory or Intolerant to Platinum-based Combination TherapyNational Cancer Center, Japan
- RECRUITINGNCT06234306Molecularly Redefining Small Bowel Adenocarcinoma to Accelerate Precision Patient CareCopenhagen University Hospital at Herlev